SCIENCEDOMAIN *international*
www.sciencedomain.org

SDI Review Form 1.6

Journal Name:	**British Journal of Pharmaceutical Research**
Manuscript Number:	**Ms_BJPR_18952**
Title of the Manuscript:	**mAb Higher Order Structure Analysis with Protein Conformational Array ELISA**
Type of the Article	**Original Research Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments		
Minor REVISION comments	1. **Key words:** use full names (abbreviation in brackets) 2. **Line 73:** explain the abbreviation EMA 3. **Lines 101-103 and 105:** include please the name of country and city for Sigma-Aldrich, Thermo Fisher and Array Bridge Inc. 4. **Antibodies and ELISA kits:** List the names of polyclonal antibodies used (pAb1-pAb31) and give their specificity (name of IgG region, sequences of aminoacids etc.) 5. **Line 115:** should be "*vice versa*" 6. **Line 117:** give the information about the temperature used 7. **Line 120:** why authors tested the pH=8, not higher? It is the pH value normally used during mAb development? If yes, write about it in the text 8. **Line 124:** how long sample was treated with PNG-ase F? Please write 9. **Lines 126**-128/9: the same information was given earlier (see lines 106-110) 10. **How about rows A and H**? What type of samples were applicated there? Give the information in the text 11. **Line 135:** give the name of country and city for the company which produced spectrophotometer	

	12. **Line 136:** how long the reaction with TMB was going? Why authors doesn't used reference filter? As far as I know wavelength correction to 540 nm or 570 nm is necessary for TMB 13. **Lines 142, 143:** why IgG1 samples were incubated at 55˚C and IgG2 at 40˚C, not at the same temperatures? What was the reason to choose such temperatures, not others? The time of incubation also differ (10 and 14 days, respectively). Explain in the text why. In my opinion the comparison of results may be done when the experiments are done under the same conditions. The differences in the results obtained may result from different temperatures used and different time of exposition. 14. **Lines 165-168:** the pH values should be done in the text. Why IgG2 wasn't examined in pH=3.6? Explain please in the text. 15. **Line 189:** "...both samples **were** tested..." (plural). 16. **Line 188-**189: why only IgG1, not IgG2, was examined in different light condition? Explain please in the text. 17. **Line 226:** citation is needed on the end of sentence. 18. **Line 235:** should be "...13-31) of this..." (31 pAb were used). 19. **Line 258:** authors can't write, that IgG1 and IgG2 samples were examined under the similar chemical and physical condition, because they were not! See my comments above. 20. **Line 268:** IgG1 and 2 were not tested at neutral condition! pH=8 is not neutral! 21. **Lines 315/316-317 and 325-326** give the same information. Please delete one of them.	

SDI Review Form 1.6

Optional/General comments	I am interested in authors opinion if PCA ELISA can be also used for IgG molecule examination in biological samples, e.g. for the comparison of some IgG regions exposition in various diseases. If yes, it will be good to write about it in the Discussion section.	

Reviewer Details:

Name:	**Anonymous**
Department, University & Country	***Wrocław Medical University, Poland***